R386-702-5. Mandatory Submission of Clinical Material

  (1) Laboratories shall submit clinical material from all cases identified with organisms listed in Subsection R386-702-5(3) to the Utah Department of Health, Utah Public Health Laboratory (UPHL) within three working days of identification.

  (a) Clinical material is defined as:

  (i) A clinical isolate containing the organism for which submission of material is required; or

  (ii) If an isolate is not available, material containing the organism for which submission of material is required, in the following order of preference:

  (A) a patient specimen,

  (B) nucleic acid, or

  (C) other laboratory material.

  (2) Laboratories submitting clinical material from cases identified with organisms designated by UPHL as potential bioterrorism agents shall first notify UPHL via telephone immediately.

  (a) UPHL can be contacted during business hours at [phone], or after hours at [phone], of all bioterrorism agents that are being submitted.

  (3) Organisms mandated for standard clinical submission include:

  (a) Antibiotic resistant organisms from any clinical specimen that meet the following criteria:

  (i) Resistant to a carbapenemin:

  (A) Acinetobacter species,

  (B) Enterobacter species,

  (C) Escherichia coli, or

  (D) Klebsiella species,

  (E) Pseudomonas aeruginosa,

  (ii) Resistant to vancomycin in:

  (A) Staphylococcus aureus (VRSA),

  (iii) Demonstrated carbapenemase production in:

  (A) Acinetobacter species,

  (B) Enterobacter species,

  (C) Escherichia coli,

  (D) Klebsiella species,

  (E) Any other Enterobacteriaceae species, or

  (F) Pseudomonas aeruginosa.

  (b) Campylobacter species;

  (c) Candida auris or Candida haemulonii from any body site;

  (d) Corynebacterium diphtheriae;

  (e) Shiga toxin-producing Escherichia coli (STEC), including enrichment and/or MacConkey broths that tested positive by any method for Shiga toxin;

  (f) Haemophilus influenzae, from normally sterile sites;

  (g) Influenza A virus, unsubtypeable;

  (h) Influenza virus (hospitalized cases only);

  (i) Legionella species;

  (j) Listeria monocytogenes;

  (k) Measles (rubeola) virus;

  (l) Mycobacterium tuberculosis complex;

  (m) Neisseria meningitidis, from normally sterile sites;

  (n) Salmonella species;

  (o) Shigella species;

  (p) Vibrio species;

  (q) West Nile virus;

  (r) Yersinia species;

  (s) Zika virus; and

  (t) Any organism implicated in an outbreak when instructed by authorized local or state health department personnel.

  (4) Organisms mandated for bioterrorism clinical submission include:

  (a) Bacillus anthracis;

  (b) Brucella species;

  (c) Clostridium botulinum;

  (d) Francisella tularensis; and

  (e) Yersinia pestis.

  (5) Submission of clinical material does not replace the requirement for laboratories to report the event to public health as defined in Sections R386-702-6 and R386-702-7.

  (6) For additional information on this process, contact UPHL at [phone].